Elanco Animal Health Incorporated (NYSE:ELAN) Receives $25.44 Consensus Price Target from Analysts

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have been assigned an average rating of “Moderate Buy” from the twelve ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $25.8889.

A number of analysts have weighed in on ELAN shares. Barclays started coverage on shares of Elanco Animal Health in a report on Tuesday, December 9th. They set an “overweight” rating and a $30.00 target price on the stock. Piper Sandler upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $24.00 to $30.00 in a research note on Thursday, January 22nd. KeyCorp restated an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, December 10th. UBS Group upped their target price on Elanco Animal Health from $27.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, January 29th. Finally, Morgan Stanley raised their price target on Elanco Animal Health from $18.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday, December 18th.

Elanco Animal Health Price Performance

Shares of NYSE ELAN opened at $24.96 on Friday. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $12.40 billion, a price-to-earnings ratio of 416.09, a price-to-earnings-growth ratio of 3.76 and a beta of 1.87. Elanco Animal Health has a twelve month low of $8.02 and a twelve month high of $26.08. The business has a 50 day simple moving average of $23.84 and a 200-day simple moving average of $21.39.

Insider Buying and Selling

In other news, CEO Jeffrey N. Simmons purchased 22,000 shares of Elanco Animal Health stock in a transaction dated Thursday, December 11th. The stock was bought at an average price of $21.75 per share, with a total value of $478,500.00. Following the completion of the acquisition, the chief executive officer owned 167,000 shares in the company, valued at $3,632,250. The trade was a 15.17% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Lawrence Erik Kurzius purchased 10,000 shares of the stock in a transaction dated Friday, December 12th. The shares were purchased at an average price of $21.30 per share, with a total value of $213,000.00. Following the transaction, the director directly owned 131,773 shares of the company’s stock, valued at approximately $2,806,764.90. The trade was a 8.21% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have purchased 43,450 shares of company stock valued at $937,883. 0.89% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Elanco Animal Health

Large investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Elanco Animal Health during the first quarter worth approximately $2,065,000. Goldman Sachs Group Inc. raised its stake in Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after acquiring an additional 2,445,872 shares in the last quarter. Empowered Funds LLC boosted its position in Elanco Animal Health by 35.2% during the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock worth $166,000 after acquiring an additional 4,121 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Elanco Animal Health by 4.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock worth $18,830,000 after purchasing an additional 76,408 shares in the last quarter. Finally, US Bancorp DE increased its holdings in shares of Elanco Animal Health by 188.4% during the second quarter. US Bancorp DE now owns 42,986 shares of the company’s stock valued at $614,000 after purchasing an additional 28,080 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.